Analyst firms · Raymond James · JNCE

Raymond James JNCE price target and rating history

Jounce Therapeutics Inc. (JNCE) · Health Care

Raymond James rates Jounce Therapeutics Inc. (JNCE) Strong Buy with a $20 price target, as of its latest action on May 6, 2022. It has published 3 rating actions on JNCE since September 2021, including 2 upgrades and 0 downgrades.

Current rating
Strong Buy
Price target
$20
Median target, all firms
Too few
Actions on JNCE
3

Raymond James price target on JNCE

$20$15$1020222023202420252026
Raymond James price target on JNCE, each point a stated target, September 2021 to May 2022.

Every Raymond James rating on JNCE

Questions about Raymond James and JNCE

What is Raymond James's price target for JNCE?
Raymond James's latest stated price target for Jounce Therapeutics Inc. (JNCE) is $20, from its action on May 6, 2022.
What is Raymond James's rating on JNCE?
Raymond James rates JNCE Strong Buy, a bullish rating, as of May 6, 2022.
When did Raymond James last change its view on JNCE?
On May 6, 2022, Raymond James upgrades to Strong Buy from Outperform, price target $15 to $20.

All Raymond James ratingsJNCE news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.